AstraZeneca launches Brilinta adherence effort

Share this article:
AstraZeneca launched a new adherence program for its antiplatelet Brilinta, dubbed Complete the Course.

Enrollees will get multichannel support services, including “Access My Brilinta,” which offers “time-saving prescription access and affordability information” to patients and providers alike, said the company.

The program, said AstraZeneca, was designed to address patient preference for how they receive medical info as they transition from hospital to home. The company conducted a patient survey finding that patients with Acute Coronary Syndrome want more info about their medications across multiple channels.

“With over one million people diagnosed with ACS every year, there is an ever increasing need for additional tools and resources that can help patients and their caregivers learn about and understand ACS,” said AstraZeneca VP for global medical affairs James Ferguson, MD. “These materials may help patients maintain their medication regimen.”

The program is built around key transition points, dubbed Learning, Reinforcement and Re-education.

Brilinta was approved in the US in July of 2011 and competes with Plavix.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.